Fig. 2: Antibody internalization is antibody and PROTAC concentration dependent and relies on degrader target-specific activity.

Internalization of Tmab, Cmab, and anti-MET was evaluated by in vitro live-cell imaging, plotted as AUC (RCU × µM²/Well/%) as previously described.a SKBR3 and BxPC-3 cell lines were treated with PROTAC SJF1528 100 nM and Tmab (4 µg/mL, 2 µg/mL, 1 µg/mL) or Cmab (4 µg/mL, 2 µg/mL, 1 µg/mL), respectively, and compared with the DMSO control conditions without PROTAC. b SKBR3 and BT-474 cells were treated with Tmab 2 µg/mL and PROTAC SJF1528 at (200 nM, 100 nM, 50 nM) or (200 nM, 100 nM), respectively, and compared with DMSO control conditions without PROTAC. c SKBR3 cells were treated with Tmab or human IgG (2 µg/mL) and PROTAC SJF1528 (200 nM) or off-target antigen specificity PROTAC SJF1521 (200 nM) or the inactive degrader SJF0661 (200 nM). HCC827 GR6 cells were treated with anti-MET or human IgG (2 µg/mL) and PROTAC 48-284 (500 nM) and inactive degrader 48-279 (500 nM). Data shown here are representative experiments, every condition has been done in triplicate and lines and error bars represent the medians and SEM Individual data points are available in the Supplementary Data file.